購物車 
-
瑞德西韋三磷酸
NMR and HPLC COA下載 MSDS下載 - Names：
GS-443902
- CAS號：
1355149-45-9
MDL Number： - MF(分子式)： C12H16N5O17P3 MW(分子量)： 531.2
- EINECS:NA Reaxys Number:
- Pubchem ID: Brand:BIOFOUNT
瑞德西韋三磷酸（GS-443902,1355149-45-9;Remdesivir triphosphate) 是一種較為有效的病毒RNA依賴的RNA聚合酶 (RdRp) 的抑制劑，對TP RdRp，RSV RdRp 和 HCV RdRp 的 IC50 分別為 5.6 μM，1.1 μM 和 5 μM。GS-443902 屬于三磷酸鹽衍生產(chǎn)物。
| 貨品編碼 | 規(guī)格 | 純度 | 價格 (￥) | 現(xiàn)價(￥) | 特價(￥) | 庫存描述 | 數(shù)量 | 總計(jì) (￥) |
|---|---|---|---|---|---|---|---|---|
| HCQ000015-1mg | 1mg | ≥95% | ￥ 4500.00 | ￥ 4500.00 | backorder | ￥ 0.00 | ||
| HCQ000015-5mg | 5mg | ≥95% | ￥ 12500.00 | ￥ 12500.00 | backorder | ￥ 0.00 | ||
| HCQ000015-20mg | 20mg | ≥95% | ￥ 22500.00 | ￥ 22500.00 | backorder | ￥ 0.00 | ||
| HCQ000015-100mg | 100mg | ≥95% | ￥ 0.00 | ￥ 0.00 | backorder | ￥ 0.00 |
- 大包裝詢價 提供各種包裝，敬請垂詢
- 收藏商品 商品點(diǎn)評 加入購物車 立即購買
| 中文別名 | 瑞德西韋三磷酸鈉鹽衍生物;瑞德西韋三磷酸;1355149-45-9;瑞德西韋衍生物;瑞德西韋三磷酸 |
| 英文別名 | GS-443902;GS 443902;GS443902;1355149-45-9;Remdesivir monophosphate；[[(2R,3S,4R,5R)-5-(4-Aminopyrrolo[2,1-f][1,2,4]triazin-7-yl)-5-cyano-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] phosphono hydrogen phosphate |
| CAS號 | 1355149-45-9 |
| Inchi | InChI=1S/C12H16N5O13P3/c13-4-12(8-2-1-6-11(14)15-5-16-17(6)8)10(19)9(18)7(28-12)3-27-32(23,24)30-33(25,26)29-31(20,21)22/h1-2,5,7,9-10,18-19H,3H2,(H,23,24)(H,25,26)(H2,14,15,16)(H2,20,21,22)/t7-,9-,10-,12+/m1/s1 |
| InchiKey | DFVPCNAMNAPBCX-LTGWCKQJSA-N |
| 分子式 Molecular Weight | C12H16N5O17P3 |
| 分子量 Formula | 531.2 |
| 溶解度Solubility | 易溶于水，不易溶于有機(jī)溶劑 |
| 性狀 | 白色粉色粉末 |
| 儲藏條件 Storage conditions | -20℃下存儲，2-3years；常溫下極容易潮解；低溫氮?dú)鈼l件下保存。 |
| 產(chǎn)品說明 | 瑞德西韋三磷酸（GS-443902,1355149-45-9,Remdesivir triphosphate) 是一種有效的病毒RNA依賴的 RNA 聚合酶 (RdRp) 的抑制劑，對 TP RdRp，RSV RdRp 和 HCV RdRp 的 IC50 分別為 5.6 μM，1.1 μM 和 5 μM。GS-443902屬于三磷酸鹽衍生產(chǎn)物。 |
| Introduction | Remdesivir triphosphate（GS-443902,1355149-45-9) IC50: 1.1 μM (RSV RdRp) and 5 μM (HCV RdRp) |
| Application1 | Remdesivir triphosphate is a is a potent viral RNA-dependent RNA-polymerases (RdRp) inhibitor. It is the active triphosphate metabolite of Remdesivir. |
| Application2 | |
| Application3 |
| 警示圖 | |
| 危險(xiǎn)性 | |
| 危險(xiǎn)性警示 | Not available |
| 安全聲明 | H332; H403 |
| 安全防護(hù) | P332+P313; P305+P351+P338 |
| 備注 | 實(shí)驗(yàn)過程防止食如、吸入 |
| 【1】. Warren TK, et al. Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeys. Nature. 2016 Mar 17;531(7594):381-5. |
| 【2】Cho A, et al. Synthesis and antiviral activity of a series of 1'-substituted 4-aza-7,9-dideazaadenosine C-nucleosides. Bioorg Med Chem Lett. 2012 Apr 15;22(8):2705-7. |
| 【3】Gilead Sciences, Foster City, California 94404, USA. |
| 【4】United States Army Medical Research Institute of Infectious Diseases, Therapeutic Development Center, Frederick, Maryland 21702, USA. |
【5】 The nucleoside analog GS-441524 strongly inhibits feline infectious peritonitis (FIP) virus in tissue culture and experimental cat infection studies B.G. Murphy, M. Perron, E. Murakami, K. Bauer, Y. Park, C. Eckstrand, M. Liepnieks, N.C. Pedersen Vet Microbiol. 2018 Jun; 219: 226–233. Published online 2018 Apr 22. doi: 10.1016/j.vetmic.2018.04.026 PMCID: PMC7117434
【6】 Development and validation of a UHPLC-MS/MS method for quantification of the prodrug remdesivir and its metabolite GS-441524: a tool for clinical pharmacokinetics of SARS-CoV-2/COVID-19 and Ebola virus disease Valeria Avataneo, Amedeo de Nicolò, Jessica Cusato, Miriam Antonucci, Alessandra Manca, Alice Palermiti, Catriona Waitt, Stephen Walimbwa, Mohammed Lamorde, Giovanni di Perri, Antonio D’Avolio J Antimicrob Chemother. 2020 May 3 : dkaa152. Published online 2020 May 3. doi: 10.1093/jac/dkaa152 PMCID: PMC7197584
【7】Efficacy and safety of the nucleoside analog GS-441524 for treatment of cats with naturally occurring feline infectious peritonitis Niels C Pedersen, Michel Perron, Michael Bannasch, Elizabeth Montgomery, Eisuke Murakami, Molly Liepnieks, Hongwei Liu J Feline Med Surg. 2019 Apr; 21(4): 271–281. Published online 2019 Feb 13. doi: 10.1177/1098612X19825701 PMCID: PMC6435921
【8】 Current knowledge about the antivirals remdesivir (GS-5734) and GS-441524 as therapeutic options for coronaviruses E. Susan Amirian, Julie K. Levy One Health. 2020 Jun; 9: 100128. Published online 2020 Mar 27. doi: 10.1016/j.onehlt.2020.100128 PMCID: PMC7118644
【9】Coronavirus Susceptibility to the Antiviral Remdesivir (GS-5734) Is Mediated by the Viral Polymerase and the Proofreading Exoribonuclease Maria L. Agostini, Erica L. Andres, Amy C. Sims, Rachel L. Graham, Timothy P. Sheahan, Xiaotao Lu, Everett Clinton Smith, James Brett Case, Joy Y. Feng, Robert Jordan, Adrian S. Ray, Tomas Cihlar, Dustin Siegel, Richard L. Mackman, Michael O. Clarke, Ralph S. Baric, Mark R. Denison mBio. 2018 Mar-Apr; 9(2): e00221-18. Published online 2018 Mar 6. doi: 10.1128/mBio.00221-18 PMCID: PMC5844999
【10】Remdesivir and SARS-CoV-2: structural requirements at both nsp12 RdRp and nsp14 Exonuclease active-sites
Ashleigh Shannon, Nhung Thi Tuyet Le, Barbara Selisko, Cecilia Eydoux, Karine Alvarez, Jean-Claude Guillemot, Etienne Decroly, Olve Peersen, Francois Ferron, Bruno Canard Antiviral Res. 2020 Apr 10 : 104793. doi: 10.1016/j.antiviral.2020.104793 [Epub ahead of print] PMCID: PMC7151495
【11】Remdesivir: A Review of Its Discovery and Development Leading to Emergency Use Authorization for Treatment of COVID-19 Richard T. Eastman, Jacob S. Roth, Kyle R. Brimacombe, Anton Simeonov, Min Shen, Samarjit Patnaik, Matthew D. Hall ACS Cent Sci. 2020 May 4 : acscentsci.0c00489. Published online 2020 May 4. doi: 10.1021/acscentsci.0c00489 PMCID: PMC7202249
【12】Artificial intelligence approach fighting COVID-19 with repurposing drugs Yi-Yu Ke, Tzu-Ting Peng, Teng-Kuang Yeh, Wen-Zheng Huang, Shao-En Chang, Szu-Huei Wu, Hui-Chen Hung, Tsu-An Hsu, Shiow-Ju Lee, Jeng-Shin Song, Wen-Hsing Lin, Tung-Jung Chiang, Jiunn-Horng Lin, Huey-Kang Sytwu, Chiung-Tong Chen Biomed J. 2020 May 15 doi: 10.1016/j.bj.2020.05.001 [Epub ahead of print] PMCID: PMC7227517
【6】 Development and validation of a UHPLC-MS/MS method for quantification of the prodrug remdesivir and its metabolite GS-441524: a tool for clinical pharmacokinetics of SARS-CoV-2/COVID-19 and Ebola virus disease Valeria Avataneo, Amedeo de Nicolò, Jessica Cusato, Miriam Antonucci, Alessandra Manca, Alice Palermiti, Catriona Waitt, Stephen Walimbwa, Mohammed Lamorde, Giovanni di Perri, Antonio D’Avolio J Antimicrob Chemother. 2020 May 3 : dkaa152. Published online 2020 May 3. doi: 10.1093/jac/dkaa152 PMCID: PMC7197584
【7】Efficacy and safety of the nucleoside analog GS-441524 for treatment of cats with naturally occurring feline infectious peritonitis Niels C Pedersen, Michel Perron, Michael Bannasch, Elizabeth Montgomery, Eisuke Murakami, Molly Liepnieks, Hongwei Liu J Feline Med Surg. 2019 Apr; 21(4): 271–281. Published online 2019 Feb 13. doi: 10.1177/1098612X19825701 PMCID: PMC6435921
【8】 Current knowledge about the antivirals remdesivir (GS-5734) and GS-441524 as therapeutic options for coronaviruses E. Susan Amirian, Julie K. Levy One Health. 2020 Jun; 9: 100128. Published online 2020 Mar 27. doi: 10.1016/j.onehlt.2020.100128 PMCID: PMC7118644
【9】Coronavirus Susceptibility to the Antiviral Remdesivir (GS-5734) Is Mediated by the Viral Polymerase and the Proofreading Exoribonuclease Maria L. Agostini, Erica L. Andres, Amy C. Sims, Rachel L. Graham, Timothy P. Sheahan, Xiaotao Lu, Everett Clinton Smith, James Brett Case, Joy Y. Feng, Robert Jordan, Adrian S. Ray, Tomas Cihlar, Dustin Siegel, Richard L. Mackman, Michael O. Clarke, Ralph S. Baric, Mark R. Denison mBio. 2018 Mar-Apr; 9(2): e00221-18. Published online 2018 Mar 6. doi: 10.1128/mBio.00221-18 PMCID: PMC5844999
【10】Remdesivir and SARS-CoV-2: structural requirements at both nsp12 RdRp and nsp14 Exonuclease active-sites
Ashleigh Shannon, Nhung Thi Tuyet Le, Barbara Selisko, Cecilia Eydoux, Karine Alvarez, Jean-Claude Guillemot, Etienne Decroly, Olve Peersen, Francois Ferron, Bruno Canard Antiviral Res. 2020 Apr 10 : 104793. doi: 10.1016/j.antiviral.2020.104793 [Epub ahead of print] PMCID: PMC7151495
【11】Remdesivir: A Review of Its Discovery and Development Leading to Emergency Use Authorization for Treatment of COVID-19 Richard T. Eastman, Jacob S. Roth, Kyle R. Brimacombe, Anton Simeonov, Min Shen, Samarjit Patnaik, Matthew D. Hall ACS Cent Sci. 2020 May 4 : acscentsci.0c00489. Published online 2020 May 4. doi: 10.1021/acscentsci.0c00489 PMCID: PMC7202249
【12】Artificial intelligence approach fighting COVID-19 with repurposing drugs Yi-Yu Ke, Tzu-Ting Peng, Teng-Kuang Yeh, Wen-Zheng Huang, Shao-En Chang, Szu-Huei Wu, Hui-Chen Hung, Tsu-An Hsu, Shiow-Ju Lee, Jeng-Shin Song, Wen-Hsing Lin, Tung-Jung Chiang, Jiunn-Horng Lin, Huey-Kang Sytwu, Chiung-Tong Chen Biomed J. 2020 May 15 doi: 10.1016/j.bj.2020.05.001 [Epub ahead of print] PMCID: PMC7227517
對不起，暫無產(chǎn)品評價！
MSDS
SDS 1.0 中文
展開
SDS 1.0 英文
展開
- 相關(guān)產(chǎn)品
-
< >
- 推薦產(chǎn)品
-
< >
- 最新產(chǎn)品
-
< >
新聞
胞爬片免疫組化染色.png)
怎么做細(xì)胞爬片免疫組化染色實(shí)驗(yàn)
細(xì)胞爬片免疫組化染色，是通過細(xì)胞爬片是讓玻片浸在細(xì)胞培養(yǎng)基內(nèi)，細(xì)胞在玻片上生長，主要用于組織學(xué)，免疫組織化學(xué)...
2020/7/20 22:04:33
提取病毒RNA的實(shí)驗(yàn)方法
提取病毒RNA方法分別有：異硫氰酸胍的提取病毒RNA方法、TRIzol LS提取法、Trizol法提取法等等...
2020/7/22 20:29:26
9月開學(xué)季——助研新學(xué)期 范德送好禮
2025/8/28 15:30:55
Waxfilm 實(shí)驗(yàn)室封口膜：技術(shù)與國際市場的雙重突破
在實(shí)驗(yàn)室耗材領(lǐng)域，封口膜是保障實(shí)驗(yàn)準(zhǔn)確性與穩(wěn)定性的關(guān)鍵產(chǎn)品之一。近年來，Waxfilm?實(shí)驗(yàn)室封口膜憑借其卓...
2025/5/13 13:03:40
Waxfilm實(shí)驗(yàn)室封口膜的5大突破
Waxfilm實(shí)驗(yàn)室封口膜作為生物功能膜領(lǐng)域的國產(chǎn)技術(shù)突破和品牌突破，是生物領(lǐng)域中國技術(shù)發(fā)展的縮影。
2025/5/6 17:02:07
各種微流控芯片鍵合方法的優(yōu)缺點(diǎn)
微流控芯片鍵合：目前主要有激光焊接、熱壓鍵合、膠鍵合、超音波焊接，每種方法都有各自的優(yōu)缺點(diǎn)。本文主要介紹聚酯...
2023/7/28 10:43:09
新一代微流控鍵合解決方案
微流控鍵合解決方案：微流控芯片制造的一個重要環(huán)節(jié)，也是最容易被忽視的--芯片鍵合。其中一個重要因素是：微流控...
2023/7/27 12:44:28
驗(yàn)動物圖.png)
熒光素鉀鹽使用說明
D-熒光素鉀鹽（K+）設(shè)計(jì)用于體外和體內(nèi)生物發(fā)光測定。D-熒光素的質(zhì)量和純度對于獲得良好和可重復(fù)的結(jié)果至關(guān)重...
2023/7/20 11:05:11
如何選BSA（牛血清白蛋白）
如何選BSA（牛血清白蛋白）：牛血清白蛋白（BSA）有多種形式，如何選擇適合自己的牛血清白蛋白（BSA）是一...
2023/2/14 13:09:18
牛血清白蛋白（BSA）常見問題
牛血清白蛋白（BSA）常見問題:牛血清白蛋白（BSA）在實(shí)驗(yàn)室中是通用的，可用于蛋白質(zhì)印跡、細(xì)胞組織培養(yǎng)、P...
2022/10/19 9:39:51
